{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:50:25Z","timestamp":1791521425210,"version":"4.3.4"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","award":["2022-1"],"award-info":[{"award-number":["2022-1"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic Retinopathy (DR) is a prevalent and sight-threatening ocular complication of diabetes, and one of the leading causes of vision loss and blindness among the working-age population worldwide. Driven by a growing understanding of the pathophysiological mechanisms underlying DR, treatment strategies have evolved from a sole focus on glycemic control to comprehensive, multi-targeted, and multimodal therapies. This study systematically summarizes the characteristics of current clinical trials focused on DR treatment and evaluates the employed research methodologies. The aim of this review is to explore methodological trends in specific domains, with the hope that such insights may inform future efforts to optimize trial design and improve trial quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study followed the PRISMA-ScR reporting guidelines. Clinical trials registered on ClinicalTrials.gov and the Chinese Clinical Trial Registry (ChiCTR) were retrieved. In addition, clinical trials indexed in PubMed from July 23, 2016 to July 23, 2026 were retrieved. Data from the included studies were extracted and presented in tabular form.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Clinical research targeting DR has expanded rapidly, reflecting a shift toward diverse interventions like anti-Vascular endothelial growth factor(anti-VEGF) drugs, laser treatments, and combined therapies. However, several methodological limitations were noted in the included studies, including the failure to specify diabetes type in over half of the cases, a predominance of small-sample trials, inconsistent reporting of intervention duration, and limited implementation of blinding due to practical constraints in ophthalmic interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review represents the first comprehensive assessment of current DR clinical research, exposing key design weaknesses in existing trials. Future meta-analyses and systematic evaluations, informed by the methodological gaps identified in this review, are urgently needed to generate robust evidence that can guide optimal treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1961622","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:27Z","timestamp":1791519987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the methodological framework of diabetic retinopathy interventional trials: a scoping review on trial design, execution, and reporting practices"],"prefix":"10.3389","volume":"17","author":[{"given":"Zixuan","family":"Wang","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwei","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Environment and Energy, Beijing University of Civil Engineering and Architecture","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanchi","family":"Yan","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Fan","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyue","family":"Zhao","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjing","family":"Shi","sequence":"additional","affiliation":[{"name":"Changchun Disabled Persons Rehabilitation Center","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/cells12091342","article-title":"Retinal cell damage in diabetic retinopathy","volume":"12","author":"Zhou","year":"2023","journal-title":"Cells"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.2289","article-title":"Prevalence of diabetic retinopathy in the US in 2021","volume":"141","author":"Lundeen","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i9.1401","article-title":"Epidemiology of type 2 diabetes in the Middle East and North Africa: Challenges and call for action","volume":"12","author":"El-Kebbi","year":"2021","journal-title":"World J Diabetes"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.3390\/jcm15103811","article-title":"Incidence and risk factors of diabetic retinopathy in patients with type 1 diabetes mellitus: A retrospective study in NGHA, Riyadh, Saudi Arabia","volume":"15","author":"Ul-Haq","year":"2026","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2023.101220","article-title":"Optical coherence tomography in the management of diabetic macular oedema","volume":"98","author":"Szeto","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3646342","article-title":"Analysis of the effect of nine consecutive years' intensive management and number of times achieving the target control on endpoint events in T2DM patients in Sanlitun Community Health Service Center in Beijing","volume":"2020","author":"Zhao","year":"2020","journal-title":"Int J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14377","article-title":"Evidence and indications for systemic treatment in diabetic retinopathy: a systematic review","volume":"98","author":"Elkjaer","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2024.03.009","article-title":"Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review","volume":"69","author":"Bressler","year":"2024","journal-title":"Surv Ophthalmol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/08820538.2026.2673068","article-title":"Repurposing fenofibrate for early diabetic retinopathy: A systemic and disease-modifying approach","volume":"41","author":"Alfaleh","year":"2026","journal-title":"Semin Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/pharmaceutics15010122","article-title":"Current treatments and innovations in diabetic retinopathy and diabetic macular edema","volume":"15","author":"Gonzalez-Cortes","year":"2023","journal-title":"Pharmaceutics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2025.04.021","article-title":"Visual field changes in diabetic retinopathy: Natural history and after pan-retinal photocoagulation in the diabetic retinopathy study and the ETDRS","volume":"9","author":"Lee","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v17i1.10175","article-title":"Update on management of non-proliferative diabetic retinopathy without diabetic macular edema; Is there a paradigm shift","volume":"17","author":"Arabi","year":"2022","journal-title":"J Ophthalmic Vis Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/2474126419893829","article-title":"American Society of Retina Specialists Clinical Practice Guidelines on the management of nonproliferative and proliferative diabetic retinopathy without diabetic macular edema","volume":"4","author":"Yonekawa","year":"2020","journal-title":"J Vitreoretin Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155774","article-title":"Inflammatory cytokines and retinal nonperfusion area in quiescent proliferative diabetic retinopathy","volume":"154","author":"Lee","year":"2022","journal-title":"Cytokine"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.3390\/cells11213362","article-title":"Diabetic macular edema: Current understanding, molecular mechanisms and therapeutic implications","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.4103\/1673-5374.390955","article-title":"On implications of somatostatin in diabetic retinopathy","volume":"19","author":"Fang","year":"2024","journal-title":"Neural Regen Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.s288065","article-title":"Overview of clinical trials on type 2 diabetes mellitus: A comprehensive analysis of the ClinicalTrials.gov database","volume":"14","author":"Long","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50688","article-title":"Publication of results of registered trials with published study protocols, 2011-2022","volume":"7","author":"Vorland","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.91a.24028","article-title":"Diabetic retinopathy: Screening, prevention, and treatment","volume":"91","author":"Chong","year":"2024","journal-title":"Cleve Clin J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12913-025-13983-0","article-title":"Barriers and facilitators to the use of tele-ophthalmology in diabetic eye care: a scoping review","volume":"26","author":"Nopour","year":"2026","journal-title":"BMC Health Serv Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03668-w","article-title":"SPIRIT 2025 statement: Updated guideline for protocols of randomized trials","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ophtha.2021.07.009","article-title":"Intravitreal pharmacotherapies for diabetic macular edema: A report by the American Academy of Ophthalmology","volume":"129","author":"Ehlers","year":"2022","journal-title":"Ophthalmology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s548241","article-title":"Nurse-led model in diabetic retinopathy screening: An exploratory scoping review of nurses' roles and contributions","volume":"19","author":"Chen","year":"2025","journal-title":"Clin Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2026.05.005","article-title":"Disorganization of inner retinal layers and disruption of outer retinal layers as predictors of anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema: A scoping review","volume":"71","author":"Nadimpalli","year":"2026","journal-title":"Surv Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0304283","article-title":"Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis","volume":"19","author":"Yao","year":"2024","journal-title":"PloS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/icu.0000000000000424","article-title":"Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: Recent clinically relevant findings from DRCR.net Protocol T","volume":"28","author":"Cai","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000502779","article-title":"The Diabetic Retinopathy Clinical Research Network (DRCR.net) and its contributions to the treatment of diabetic retinopathy","volume":"62","author":"Sun","year":"2019","journal-title":"Ophthalmic Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: Systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40662-024-00389-y","article-title":"Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema","volume":"11","author":"Yao","year":"2024","journal-title":"Eye Vis (Lond)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/bioengineering12121342","article-title":"Artificial intelligence in diabetic retinopathy and diabetic macular edema: A narrative review","volume":"12","author":"Jukic","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106904","article-title":"Anti-VEGF combined with ocular corticosteroids therapy versus anti-VEGF monotherapy for diabetic macular edema focusing on drugs injection times and confounding factors of pseudophakic eyes: A systematic review and meta-analysis","volume":"196","author":"Chen","year":"2023","journal-title":"Pharmacol Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.34172\/aim.34506","article-title":"High-sensitivity C-reactive protein and its association with diabetic retinopathy: A cross-sectional study","volume":"28","author":"Faghih Abdollahi","year":"2025","journal-title":"Arch Iran Med"},{"key":"B36","article-title":"The unfinished story: Analyzing publication rates in diabetic retinopathy and diabetic macular edema trials before the COVID-19 era (1972-2018)","volume":"109","author":"Khatri","year":"2026","journal-title":"R I Med J (2013)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002423","article-title":"Finding the right power balance: Better study design and collaboration can reduce dependence on statistical power","volume":"22","author":"Nakagawa","year":"2024","journal-title":"PLoS Biol"},{"key":"B38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s41433-021-01750-4","article-title":"Disentangling the association between retinal non-perfusion and anti-VEGF agents in diabetic retinopathy","volume":"36","author":"Chatziralli","year":"2022","journal-title":"Eye (Lond)"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1961622\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T04:26:28Z","timestamp":1791519988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1961622\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":38,"alternative-id":["10.3389\/fendo.2026.1961622"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1961622","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"article-number":"1961622"}}